Relation Between Thin-Section Computed Tomography and Clinical Findings of Mucinous Adenocarcinoma

Watanabe, Hajime; Saito, Haruhiro; Yokose, Tomoyuki; Sakuma, Yoshiki; Murakami, Shuji; Kondo, Tetsuro; Oshita, Fumihiro; Ito, Hiroyuki; Nakayama, Haruhiko; Yamada, Katsushi; Iwazaki, Masayuki

doi:10.1016/j.athoracsur.2014.10.065

Cited by 56 publications

(60 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 When evaluating recurrence risk in pN0M0 cases, it is important to exclude cases that are curable by complete resection. IMA should likewise be excluded from such analyses because this subtype is a variant of invasive adenocarcinoma 5 that is moderately to highly 30,32,33 Cases with relatively high malignancy that do not harbor EGFR mutations are not suitable for inclusion in analyses of the prognostic impact of EGFR mutation status. In fact, the proportion of EGFR mutation-positive cases among AIS and MIA were high, while the recurrence rate of IMA was not particularly low (n = 2, 18.2%) in this study.…”

Section: Discussionmentioning

confidence: 99%

Increased risk of recurrence in resected EGFR‐positive pN0M0 invasive lung adenocarcinoma

et al. 2018

View full text Add to dashboard Cite

BackgroundThis study was conducted to evaluate the prognostic and recurrent impact of EGFR mutation status in resected pN0M0 lung adenocarcinoma with consideration of the histological subtype.MethodsFollowing retrospective analysis of whole 474 consecutive pathological N0M0 lung adenocarcinoma patients, the prognostic significance of EGFR mutation status was evaluated in limited 394 subjects. Overall survival and recurrence‐free interval (RFI) were estimated using the Kaplan–Meier method and compared using a log‐rank test. Univariate and multivariate analyses were performed using Cox proportional hazard models.ResultsThe five‐year RFI was 85.7% and 93.3% for EGFR positive (n = 176) and negative (n = 218) cases, respectively (hazard ratio [HR] 1.992, 95% confidence interval [CI] 1.005–3.982; P = 0.048). Following the exclusion of specific subtypes free from recurrence or EGFR mutation (adenocarcinoma in situ, minimally invasive adenocarcinoma, and invasive mucinous adenocarcinoma), the five‐year RFI was obviously poorer in EGFR positive compared to negative cases (80.7% and 92.1%, respectively; HR 2.163, 95% CI 1.055–4.341; P = 0.035). Multivariate analysis excluding the specific subtypes confirmed that male sex, age, current or Ex‐smoking status, pleural invasion, and EGFR‐positive status were independently associated with shorter RFI. No significant differences in five‐year overall survival were found between the EGFR mutation positive and negative groups (88.7% and 93.7%, respectively; HR 1.630, 95% CI 0.787–3.432; P = 0.2).Conclusion EGFR mutations are associated with recurrence in pN0M0 lung adenocarcinoma. EGFR mutation status and histological subtype should be considered when evaluating the risk of recurrence in resected lung adenocarcinoma patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Increased risk of recurrence in resected EGFR‐positive pN0M0 invasive lung adenocarcinoma

et al. 2018

View full text Add to dashboard Cite

show abstract

“…This radiologic-pathologic correlation is not established in invasive mucinous adenocarcinomas, mucinous AIS, or mucinous MIA, which usually show nodules of consolidation with frequent air bronchograms on CT. 2,69 Furthermore, the prognostic significance of lepidic versus invasive components is not well documented in these tumors as it is in nonmucinous adenocarcinomas. 2 Therefore, the following recommendations are applicable only to nonmucinous adenocarcinomas with a lepidic component.…”

Section: Ct Features Of Mia T1mimentioning

confidence: 99%

The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer

Asamura¹,

Bankier²,

Beasley³

et al. 2016

Journal of Thoracic Oncology

557

458

View full text Add to dashboard Cite

This article proposes codes for the primary tumor categories of adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) and a uniform way to measure tumor size in part-solid tumors for the eighth edition of the tumor, node, and metastasis classification of lung cancer. In 2011, new entities of AIS, MIA, and lepidic predominant adenocarcinoma were defined, and they were later incorporated into the 2015 World Health Organization classification of lung cancer. To fit these entities into the T component of the staging system, the Tis category is proposed for AIS, with Tis (AIS) specified if it is to be distinguished from squamous cell carcinoma in situ (SCIS), which is to be designated Tis (SCIS). We also propose that MIA be classified as T1mi. Furthermore, the use of the invasive size for T descriptor size follows a recommendation made in three editions of the Union for International Cancer Control tumor, node, and metastasis supplement since 2003. For tumor size, the greatest dimension should be reported both clinically and pathologically. In nonmucinous lung adenocarcinomas, the computed tomography (CT) findings of ground glass versus solid opacities tend to correspond respectively to lepidic versus invasive patterns seen pathologically. However, this correlation is not absolute; so when CT features suggest nonmucinous AIS, MIA, and lepidic predominant adenocarcinoma, the suspected diagnosis and clinical staging should be regarded as a preliminary assessment that is subject to revision after pathologic evaluation of resected specimens. The ability to predict invasive versus noninvasive size on the basis of solid versus ground glass components is not applicable to mucinous AIS, MIA, or invasive mucinous adenocarcinomas because they generally show solid nodules or consolidation on CT.

show abstract

“…Two recent studies have discussed subtypes of IMA according to computed tomography (CT) findings; reportedly, these subtypes are closely related to the clinical outcomes of IMA patients 8,9. However, sufficient evidence of optimal management based on IMA subtypes does not yet exist.…”

Section: Introductionmentioning

confidence: 99%

Clinicopathological and immunohistochemical features of lung invasive mucinous adenocarcinoma based on computed tomography findings

Shimizu

Okita

Saisho

et al. 2016

OTT

View full text Add to dashboard Cite

BackgroundWe performed an analysis to clarify differences in clinicopathological and molecular features of lung invasive mucinous adenocarcinoma (IMA) based on computed tomography (CT) findings and their impact on prognosis.Patients and methodsOn the basis of CT findings, we divided lung IMA into three subtypes: solid, bubbling, and pneumonic. We then investigated differences in clinicopathological characteristics, prognosis, and the expressions of well-identified biomarkers, including cyclooxygenase-2 (Cox-2), excision repair cross-complementation group 1 (ERCC1), ribonucleotide reductase M1 (RRM1), class III beta-tubulin, thymidylate synthase (TS), secreted protein acidic and rich in cysteine (SPARC), programmed cell death-1 ligand-1 (PD-L1), and epidermal growth factor receptor mutation, among the three subtypes.ResultsA total of 29 patients with resected lung IMA were analyzed. Compared with the solid or bubbling type, the pneumonic type had a higher proportion of symptoms, a larger tumor size, a higher pathological stage, and a significantly worse prognosis. The immunohistochemical findings tended to show high expression of RRM1, class III beta-tubulin, and Cox-2 in the tumor and of SPARC in the stroma, but not of ERCC1, TS, and PD-L1 in the tumor. None of the biomarkers with high expression levels in the tumor were prognostic biomarkers, but the expression of SPARC in the stroma was correlated with a poor outcome.ConclusionClinical and pathological features, in conjunction with molecular data, indicate that IMA should be divided into different subgroups. In our results, the pneumonic type was correlated with a significantly worse outcome. Further studies should be performed to confirm our conclusion and to explore its molecular implications.

show abstract

Relation Between Thin-Section Computed Tomography and Clinical Findings of Mucinous Adenocarcinoma

Cited by 56 publications

References 29 publications

Increased risk of recurrence in resected EGFR‐positive pN0M0 invasive lung adenocarcinoma

Increased risk of recurrence in resected EGFR‐positive pN0M0 invasive lung adenocarcinoma

The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer

Clinicopathological and immunohistochemical features of lung invasive mucinous adenocarcinoma based on computed tomography findings

Contact Info

Product

Resources

About